Who is sponsoring NCT04478019?

NCT04478019 is sponsored by University of Wisconsin, Madison.

What drugs are being tested in NCT04478019?

Interventions in NCT04478019: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse.

What condition does NCT04478019 study?

NCT04478019 studies COVID-19, SARS-CoV 2.

Is NCT04478019 still recruiting?

NCT04478019 is currently completed. Last updated 14 July 2022.

Last reviewed 2022-07-14 · How we verify

NCT04478019: SHIELD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

Completed EARLY_PHASE1 Last updated 14 July 2022

What this trial tests

EARLY_PHASE1 trial testing 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse in COVID-19 in 245 participants. Completed in 30 June 2022.

Timeline

7 July 2020

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	University of Wisconsin, Madison
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	prevention
Enrollment	245
Start date	7 July 2020
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across United States

Drugs / interventions tested

10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV 2 — all drugs for SARS-CoV 2 →

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with COVID-19 or SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Essential workers in positions with increased likelihood of exposure to SARS-CoC-2 will be most impacted by the proposed project. Evidence has shown that the SARS-CoV-2 novel coronavirus is easily transmissable through close contact between individuals, especially during aerosol-generating procedures such as intubation of patients. The intervention proposed in this study (nasal and oral decontamination with povidone-iodine and chlorhexidine, respectively) presents an opportunity for a safe, effective, and feasible treatment to decontaminate the primary entry points for SARS-CoV-2. As such, the intervention to be studied in this project may protect healthcare and other essential workers by preventing transmission of SARS-CoV-2 from patients to healthcare workers, as well as the general public to essential worker,. and thus reducing the incidence of COVID-19 in these workers.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Review of the use of nasal and oral antiseptics during a global pandemic.
Stathis C, Victoria N, Loomis K, Nguyen SA, et al · · 2021 · cited 21× · PMID 33464122 · DOI 10.2217/fmb-2020-0286
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
Scarabel L, Guardascione M, Dal Bo M, Toffoli G. · · 2021 · cited 12× · PMID 33476760 · DOI 10.1016/j.ijid.2021.01.035
Genomic investigation to identify the source of SARS-CoV-2 infection among healthcare personnel
· 2022
Effect of COVID-19 vaccination on transmission among healthcare workers in South Korea
· 2022
The SHIELD Study: A preliminary analysis of nasal and oral antisepsis to prevent COVID-19
· 2022

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
NCT07470723 — The ORIGIN-FH Study · NA · recruiting
NCT06975657 — Well-being Skills for Reentry · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04478019 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
Last refreshed: 14 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04478019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing